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Eﬀects of a 12-week high-α-linolenic acid
intervention on EPA and DHA concentrations in
red blood cells and plasma oxylipin pattern in
subjects with a low EPA and DHA status†
Theresa Greupner, ‡a Laura Kutzner,‡b Fabian Nolte,b Alena Strangmann,a
Heike Kohrs,a Andreas Hahn,a Nils Helge Schebbb,c and Jan Philipp Schuchardt*a
The essential omega-3 fatty acid alpha-linolenic acid (ALA, 18:3n3) can be converted into EPA and DHA.
The aim of the present study was to determine the eﬀect of a high-ALA diet on EPA and DHA levels in red
blood cells (RBCs) and their oxylipins in the plasma of subjects with a low EPA and DHA status. Fatty acid
concentrations [µg mL−1] and relative amounts [% of total fatty acids] in the RBCs of 19 healthy men
(mean age 26.4 ± 4.6 years) were analyzed by means of GC-FID. Free plasma oxylipin concentrations
were determined by LC-MS based targeted metabolomics. Samples were collected and analyzed at base-
line (week 0) and after 1 (week 1), 3 (week 3), 6 (week 6), and 12 (week 12) weeks of high dietary ALA
intake (14.0 ± 0.45 g day−1). ALA concentrations signiﬁcantly (p < 0.001) increased from 1.44 ± 0.10 (week
0) to 4.65 ± 0.22 (week 1), 5.47 ± 0.23 (week 3), 6.25 ± 0.24 (week 6), and 5.80 ± 0.28 (week 12) µg mL−1.
EPA concentrations increased from 6.13 ± 0.51 (week 0) to 7.33 ± 0.33 (week 1), 8.38 ± 0.42 (p = 0.021,
week 3), 10.9 ± 0.67 (p < 0.001, week 6), and 11.0 ± 0.64 (p < 0.001, week 12) µg mL−1. DHA concen-
trations unexpectedly decreased from 41.0 ± 1.93 (week 0) to 37.0 ± 1.32 (week 1), 36.1 ± 1.37 (week 3),
35.1 ± 1.06 (p = 0.010, week 6), and 30.4 ± 1.09 (p < 0.001, week 12) µg mL−1. Relative ΣEPA + DHA
amounts were unchanged during the intervention (week 0: 4.63 ± 0.19, week 1: 4.67 ± 0.16, week 3:
4.61 ± 0.13, week 6: 4.73 ± 0.15, week 12: 4.52 ± 0.11). ALA- and EPA-derived hydroxy- and dihydroxy-
PUFA increased similarly to their PUFA precursors, although in the case of ALA-derived oxylipins, the con-
centrations increased less rapidly and to a lesser extent compared to the concentrations of their precursor
FA. LA-derived oxylipins remained unchanged and arachidonic acid and DHA oxylipin concentrations
were not signiﬁcantly changed. Our results conﬁrm that the intake of ALA is not a suﬃcient source for the
increase of EPA + DHA in subjects on a Western diet. Speciﬁcally, a high-ALA diet results in increased EPA
and declined DHA concentrations. However, the changes eﬀectively balance each other out so that
ΣEPA + DHA in RBCs – which is an established marker for health protective eﬀects of omega-3-PUFA –
remains constant. The PUFA levels in RBCs reﬂect the concentration and its changes in plasma hydroxy-
and dihydroxy-PUFA concentrations for ALA and EPA.
Introduction
Health benefits including lower risk of cardiovascular disease
and mortality,1–5 reduction of inflammatory conditions,2,6
angiogenesis, tumor growth and metastasis2,7 and a better
visual and neurological development8 are associated with long
chain (LC) omega-3 (n3) polyunsaturated fatty acids (PUFAs),
namely eicosapentaenoic acid (EPA, C20:5n3) and docosahex-
aenoic acid (DHA, C22:6n3). The positive health eﬀects are
believed to be mediated in part by the oxylipins formed from
EPA and DHA in the arachidonic acid (AA, C20:4n6) cascade
via diﬀerent enzymatic pathways: cyclooxygenase (COX) action
leads to prostanoid formation, lipoxygenases (LOX) give rise to
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hydroperoxy-PUFA which can be reduced to hydroxy-PUFA,
whereas cytochrome P450 (CYP) enzymes act as epoxygenases
and ω-hydroxylases.9,10 Epoxy-PUFA can be hydrolyzed to the
corresponding diols by soluble epoxide hydrolase (sEH).11
Additionally, EPA and DHA can also be converted to oxidative
products by autoxidation.10
The primary dietary source of EPA and DHA is oily cold
water fish such as salmon, tuna, herring and mackerel. In
most Western diets, the intake of EPA and DHA is low due to
low fish consumption. In the U.S. the daily mean EPA and
DHA intake of adults is 30–40 mg and 70–80 mg, respect-
ively.12 In Germany, the median EPA and DHA intake is
65–78 mg and 107–135 mg, respectively.13 Thus, the intake of
EPA and DHA is about 2.5- to 5-fold lower compared to the rec-
ommendation of a minimum intake of 500 mg EPA and DHA
per day for cardiovascular health.14 Another source of LC n3
PUFAs is the essential fatty acid alpha-linolenic acid (ALA,
C18:3n3), which is present in high amounts in plant oils, par-
ticularly linseed, chia, perilla and walnut oil. The essential n3
fatty acid ALA can be converted into EPA, docosapentaenoic
acid (DPAn3, C22:5n3) and DHA in a multistep elongation and
desaturation reaction.15 However, several studies, including
studies with stable isotopes, suggest that the conversion rate
from ALA to EPA (5–8%), to DPAn3 (5–8%) and especially to
DHA (0.5–5%) is low in subjects on a Western diet16–18 as
reviewed in ref. 19–21. One reason is the high intake of the
essential omega-6 (n6) PUFA linoleic acid (LA, C18:2n6), which
competes with ALA for the rate-limiting enzyme Δ6-desaturase
transforming LA into gamma-linolenic acid (GLA, C18:3n6)
while blocking ALA into stearidonic acid (C18:4 n3).22–25
The mean intake of ALA and LA in the U.S. is 1.5–1.6 g d−1
and 15.1–15.9 g d−1,12 respectively, while the median intake of
ALA and LA in Germany is 0.9–1.3 g d−1 and 7.3–10.1 g d−1,
respectively.13 The LA intake is particularly high in the U.S.
due to the high consumption of LA-rich plant oils such as
corn, sunflower, and soybean oil.26 Although the intake rec-
ommendations for ALA (1.1–1.6 g d−1) and LA (12–17 g d−1) in
the U.S.27 and Germany (ALA: 1.1 g d−1, LA: 5.4 g d−1 calcu-
lated on the basis of 0.5% of total energy (en%) and 2.5 en%,
respectively, and 2000 kcal d−1 (ref. 28)) are basically met, the
blood levels of EPA and DHA in the general population of both
countries are low29 probably due to the overall low n3 PUFA
intake and the resulting high LA/ALA ratio (about 11 : 1 in the
U.S. and 8–10 : 1 in Germany). The low levels of EPA and DHA
in RBCs, i.e. omega-3 index, are associated with an increased
risk of death from cardiovascular disease,30 neurodegeneration
and cognitive impairment31,32 and total mortality.33,34
The question whether low LC n3 PUFA blood levels can be
increased by supplementing ALA-rich oils remains controver-
sial. Few studies have investigated the eﬀect of supplementing
ALA on blood EPA and DHA content in subjects with a low LC
n3 PUFA status on a Western diet. Li et al.35 studied the eﬀect
of moderate-ALA diet (3.7 ± 1.4 g d−1) and high-ALA diet
(15.4 ± 7.5 g d−1) in vegetarians, while Fokkema et al.36 observed
the eﬀect of a short-term low-dose ALA-enriched diet (2.01 g d−1)
in vegans. The eﬀect of a high-ALA diet on absolute LC PUFA
concentrations in red blood cells (RBCs) has not been studied
in a long-term study with healthy omnivores.
The aim of the present study was therefore to determine the
short (1 and 3 weeks) and long term (6 and 12 weeks) eﬀect of
a high-ALA diet providing a daily ALA dose of 14.0 ± 0.45 g on
EPA and DHA concentrations and relative EPA and DHA
amounts in RBCs and their oxylipins in the plasma of subjects
with a low EPA and DHA status consuming a Western
(German) diet.
Materials and methods
This investigator initiated study was conducted according to
the guidelines laid down in the Declaration of Helsinki and all
procedures involving human subjects were approved by the
ethics committee at the medical chamber of Lower Saxony
(Hannover, Germany). Written informed consent was obtained
from all subjects. The study is registered in the German clini-
cal trial register (no. DRKS00006765).
Study design
The study was conducted at the Institute of Food Science and
Human Nutrition, Leibniz University Hannover, Germany and
consisted of a screening phase, a 12-week lasting intervention
period and an 8-week lasting follow-up period. During the
intervention period, five examinations were carried out, at the
beginning (week 0) and after one (week 1), three (week 3), six
(week 6) and twelve (week 12) weeks. Two further examinations
were carried out in the follow-up period (week 14 and week
20). During the intervention period, the subjects daily ingested
22.3 g of linseed oil (All Organic Trading GmbH, Kempten,
Germany) with an ALA content of 58% of total fatty acids
(Table S1†). Hence, the ALA intake from linseed oil was 12.9
g day−1. The peroxide value of the linseed oil was 1.0 meq kg−1
and the acid value was 0.28 mg KOH per g.
During each visit, fasting blood was collected, blood
pressure was measured and the subjects completed a question-
naire to obtain information about changes in medication, life-
style habits (e.g. physical activity), and tolerability of linseed
oil. The questionnaire additionally included questions about
dietary changes during the study. Moreover, the participants
were requested to restrict their dietary n3 PUFA intake four
weeks before and throughout the study, e.g. abstain from fatty
fish (salmon, herring, tuna and mackerel) and ALA-rich vege-
table foodstuﬀs such as linseeds, chia or walnuts (including
oils), to minimize the eﬀects on the variability of ALA and LC
PUFA intake and blood levels. Prior to visit week 0, week 6,
and week 12, the subjects completed a 3-day dietary question-
naire including two working days and one weekend day. The
dietary questionnaires were analyzed using PRODI (Nutri-
Science GmbH, Freiburg, Germany) to obtain the data on
energy and nutrient intake. The total ALA intake was calcu-
lated retrospectively by adding the ALA intake from the back-
ground diet to the ALA dose from the linseed oil intake.
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Blood samples were collected in the morning between 6:30
and 11:00 a.m. after overnight fasting. The examinations were
scheduled at the same time for each subject. The samples were
obtained by venipuncture of an arm vein using Multiflyneedles
(Sarstedt, Nümbrecht, Germany) into serum and EDTA monov-
ettes (Sarstedt). For the analysis of fatty acids in the plasma,
EDTA blood monovettes were centrifuged for 10 min at 1500g
and 4 °C and the plasma was transferred into 1.5 mL plastic
tubes (Sarstedt) and immediately frozen and stored at −80 °C
until extraction and analysis. For the analysis of fatty acids in
RBCs, the cell sediment after centrifugation for 10 min at
1500g and 4 °C and removal of the plasma was washed twice
with PBS (containing 1.5 mg mL−1 EDTA). Finally, the RBCs
were reconstituted in PBS to the initial blood volume, trans-
ferred into 1.5 mL Eppendorf tubes and immediately frozen
and stored at −80 °C until extraction and analysis. All transfer
steps were carried out on ice. Other sets of blood samples
(serum and EDTA monovettes) were sent to external labora-
tories for the measurement of clinical parameters. Serum lipid
levels, liver enzymes and small blood picture were determined
in the LADR laboratory (Laborärztliche Arbeitsgemeinschaft
für Diagnostik und Rationalisierung e.V.), Hannover,
Germany.
Study population
Participants were recruited from the general population in
Hannover, Germany through advertisements. Several selection
criteria were defined to assemble a homogeneous study collec-
tive. In particular, only men within a narrow age range from 20
to 40 years were included to minimize potential fluctuations in
lipid profiles due to age or hormonal influence. Subjects were
preselected via screening questionnaires according to the fol-
lowing inclusion criteria: male sex, age between 20 and 40
years, body mass index (BMI) between 20 and 27 kg m−2, and
mixed diet with low meat and fish consumption. The exclusion
criteria were defined as follows: smoking, serum triglyceride
levels ≥150 mg dl−1 (≥1.7 mmol l−1), serum total cholesterol
levels ≥200 mg dl−1 (≥5.2 mmol l−1), a relative amount of
ΣEPA + DHA in whole blood ≤3 and ≥6%, intake of fish (>2
times per week) as well as addiction to alcohol, drugs and/or
medications and diseases: chronic diseases (e.g. malignant
tumors, manifest cardiovascular disease, insulin-dependent
type 1 and 2 diabetes, and severe renal or liver diseases);
chronic gastrointestinal disorders (especially small intestine,
pancreas, and liver) as well as prior gastrointestinal surgical pro-
cedures (e.g. gastrectomy); hormonal disorders (e.g. Cushing’s
syndrome and untreated hyperthyroidism); uncontrolled hyper-
tension; blood coagulation disorders and intake of coagulation-
inhibiting drugs; periodic intake of laxatives; intake of anti-
inflammatory drugs (including acetylsalicylic acid); and intake
of lipid lowering drugs or supplements during the last
3 months before baseline examination. The inclusion and exclu-
sion criteria were assessed via questionnaires. The pre-selected
subjects were invited for a screening examination to collect
fasting blood for the analysis of serum lipid levels, liver
enzymes and fatty acid profiles in whole blood.
Fatty acid analysis
The concentrations of fatty acids were determined by means of
gas chromatography (GC) with flame ionization detection as
described37 with slight modifications. In brief, lipids were
extracted with MTBE/MeOH and derivatized with methanolic
hydrogen chloride, and the resulting fatty acid methyl esters
(FAME) were quantified using methyl pentacosanoate (C25:0
FAME) as the internal standard (IS). In addition to the deter-
mined concentration, reported as µg fatty acid per mL blood,
the relative amount (% of total fatty acids) of each fatty acid
was calculated directly based on peak areas as described.37
Oxylipin analysis
The concentrations of oxylipins in the plasma were determined
by means of an established liquid chromatography-mass
spectrometry (LC-MS) based targeted metabolomics platform
(Table S2†) as described38–40 with slight modifications. In
brief, after the addition of the IS and antioxidant solution, the
plasma samples were diluted with 1 M sodium acetate in
water : MeOH (95 : 5 v : v) adjusted to pH 6.0 with acetic acid.
Additionally, 10 µL of a solution of the LOX inhibitor 2-(1-
thienyl)ethyl 3,4-dihydroxybenzylidenecyanoacetate (2 µM) and
the protease inhibitor phenylmethylsulfonyl fluoride (5 mM)
was added. The extraction was carried out on a nonpolar
(C8)/anion exchange mixed mode material (Bond Elut Certify
II, 200 mg, Agilent) utilizing ethyl acetate/n-hexane (75 : 25,
v : v) with 1% acetic acid as the eluent. The LC-MS measure-
ment was carried out in scheduled selected reaction monitor-
ing following negative electrospray ionization and the quanti-
fication of oxylipins was performed by external calibration
utilizing 13 deuterated IS.38–40
Calculations and statistics
The results of anthropometrical measures, serum lipid levels,
dietary energy and fat intake are presented as mean ± standard
deviation (SD), while the PUFA levels in RBC membranes and
their relative change (%) are presented as mean ± standard
error (SE). If the concentration of an analyte was below the
lower limit of quantification (LLOQ) in more than 50% of the
samples at one time point, the LLOQ is given for this analyte.
Relative changes in the variables (v) were calculated individu-
ally for each subject at each time point (x) as Δ%, calculated
by: Δ% = 100 × (vtx − vweek 0)/vweek 0.
The activities of delta-5 desaturase (D5D) and delta-6 desa-
turase (D6D) were calculated using product-to-precursor ratios:
(C20:4n6/C20:3n6) and (C20:3n6/C18:2n6), respectively, as pre-
viously described.41 The indices of highly unsaturated fatty
acids (HUFA) were calculated as follows: % n3 in HUFA = 100 ×
(C20:5n3 + C22:5n3 + C22:6n3)/(C20:3n6 + C20:4n6 + C22:4n6 +
C20:5n3 + C22:5n3 + C22:6n3); % n6 in HUFA = 100 ×
(C20:3n6 + C20:4n6 + C22:4n6)/(C20:3n6 + C20:4n6 + C22:4n6 +
C20:5n3 + C22:5n3 + C22:6n3), modified from ref. 42.
The distributions of the sample sets were analyzed by
means of the Kolmogorov–Smirnov test. The diﬀerences
between baseline (week 0) levels and diﬀerent time points
Food & Function Paper
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after high-ALA diet (week 1, week 3, week 6, week 12) as well as
between week 12 and week 14 and week 20 were analyzed by
ANOVA for repeated measurements with the acceptance of stat-
istical significance at p ≤ 0.05. To determine the statistical sig-
nificance between baseline levels and each time point (as well
as between week 12 and week 14 and week 20), t-tests for
paired samples were carried out. For t-tests, the significance
levels were adjusted according to the Holm–Bonferroni
method. All statistical analyses were carried out with the SPSS
software (Version 24, SPSS Inc., Chicago, IL, USA).
Results
Study population
Twenty male subjects met the criteria and thus were included
in the study. All participants (mean age 26.2 ± 4.53 years) were
healthy and had a normal BMI (24.9 ± 2.0 kg m−2) and serum
lipid profile (Table 1). The eating habits (especially fish con-
sumption) and the physical activity of the probands did not
change during the intervention period as investigated by
dietary questionnaires. The study collective consumed a
normal mixed diet (including meat) with low fish consump-
tion (≤1 fish serving per week) and low fruit and vegetable con-
sumption (1–2 portions per day) and had a medium physical
activity status (3–5 hours of sports per week) and a high edu-
cation level (advanced technical college certificate). One
subject withdrew his consent after 1 week of the intervention.
All other 19 participants completed the 12-week intervention
period and attended at all five intervention time points. At
week 14 of the follow-up period, only 17, and at week 20, 13
participants attended the examinations. Linseed oil was well
tolerated and no adverse eﬀects were reported during the inter-
vention period.
The evaluation of the 3-day dietary questionnaires showed
that the variability of PUFA intake other than ALA was minimal
(Table 2). For LA, AA, EPA, DPAn3 and DHA intake, no signifi-
cant changes occurred during the intervention period. The
intake of ALA from the background diet was low with minimal
variability. The total ALA intake was 1.39 ± 1.31 g d−1 at week 0,
13.9 ± 0.34 g d−1 at week 6 and 14.0 ± 0.53 g d−1 at week 12.
Due to the high-ALA diet, the total PUFA intake significantly
(p < 0.001) increased from week 0 (11.2 ± 7.02 g d−1) to week 6
(23.3 ± 3.14 g d−1) and week 12 (22.9 ± 5.87 g d−1). The energy
and total fat intake did not change significantly; however,
the energy intake was lower at week 12 (2403 ± 524 kcal d−1)
compared to week 0 (2910 ± 1181 kcal d−1) and week 6 (2924 ±
820 kcal d−1) (Table 2). In addition, for saturated fatty acid (SFA)
and monounsaturated fatty acid (MUFA) intake, no significant
changes were detected during the intervention period. The
intake of SFA decreased (n.s.) from week 0 (31.1 ± 15.5 g d−1) to
week 6 (26.9 ± 11.0 g d−1) and week 12 (24.4 ± 9.83 g d−1).
Although not significant, the intake of EPA, DPAn3 and DHA
slightly decreased during the intervention period (Table 2).
Body weight, BMI, blood pressure and total cholesterol (TC)
levels were unchanged during the intervention (Table 1). Also, Ta
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low density lipoprotein (LDL), high density lipoprotein (HDL)
and triglyceride (TG) levels did not change during the interven-
tion period even though statistically significant lower LDL
levels (108 ± 18.5 to 96.9 ± 16.6 mg dl−1) were detected after
1 week (no significant diﬀerences after 3, 6 and 12 weeks).
Changes of fatty acid profile in RBCs
At baseline, the relative amount of ΣEPA + DHA in the RBCs of
the study collective was 4.63 ± 0.19% of total fatty acids
(Table 3). Thus, all subjects had a low ΣEPA + DHA status
within a narrow range.
Prior to the intervention, AA was present in the highest con-
centrations in the RBCs (150 ± 3.90 µg mL−1) among all
PUFAs, followed by LA (104 ± 3.60 µg mL−1), DHA (41.0 ±
1.93 µg mL−1), C22:4n6 (31.6 ± 1.01 µg mL−1), DPAn3 (25.9 ±
0.82 µg mL−1) and EPA (6.13 ± 0.51 µg mL−1) (Table 3). The ALA
concentrations in the RBCs were low with 1.44 ± 0.10 µg mL−1
at week 0. In the course of the high-ALA diet, the concentrations
and relative amount of ALA, EPA and DPAn3 in the RBCs
(Fig. 1A–C) increased significantly and decreased again in the
follow-up period, whereas the DHA concentrations decreased in
response to the high-ALA diet (Fig. 1D). In the following, only
the concentrations are discussed unless the relative fatty acid
distribution showed a diﬀerent trend. It is noteworthy that the
relative amount of ΣEPA + DHA in the RBCs did not change in
response to the high-ALA diet (Table 3).
The ALA concentrations in the RBCs increased time-depen-
dently (p < 0.001) from 1.44 ± 0.10 µg mL−1 (week 0) to 4.65 ±
0.22 µg mL−1 (week 1) and 5.47 ± 0.23 µg mL−1 (week 3) corres-
ponding to a mean change of 238 ± 24% and 294 ± 23%,
respectively (Table 3, Fig. 1A). The highest ALA levels (6.25 ±
0.24 µg mL−1) were observed after 6 weeks of the high-ALA
diet. In the follow-up period, the ALA concentrations dropped
(p < 0.001) rapidly from 5.80 ± 0.28 µg mL−1 at week 12 to
2.62 ± 0.16 µg mL−1 after 2 weeks (week 14) and 2.27 ± 0.21
µg mL−1 after 8 weeks (week 20) (Table S3†).
The EPA levels in the RBCs increased linearly and almost
doubled (p < 0.001) in concentration from baseline (6.13 ±
0.51 µg mL−1) to 10.9 ± 0.67 µg mL−1 at week 6 and 11.0 ±
0.64 µg mL−1 at week 12 (Table 3, Fig. 1B). In the follow-up
period, the concentrations decreased more slowly compared to
ALA with 10.0 ± 0.52 µg mL−1 after 2 weeks (week 14) and
8.53 ± 0.69 µg mL−1 after 8 weeks (week 20) (Table S3†).
The changes in DPAn3 concentrations were smaller and
only significant after 6 (p = 0.033) and 12 weeks (p = 0.014) of
the high-ALA diet, whereas the changes of the relative
amounts were statistically significant (p < 0.001) after 3, 6 and
12 weeks (Table 3, Fig. 1C). From baseline to week 12, the
DPAn3 concentrations increased from 25.9 ± 0.51 µg mL−1 to
32.3 ± 1.35 µg mL−1 and remained high over the follow-up
period (35.3 ± 1.63 µg mL−1 at week 14 and 32.6 ± 1.49 at week
20) (Table S3†).
A linear and significant (p < 0.001) reduction of DHA con-
centrations was observed between baseline (41.0 ± 1.93
µg mL−1) and week 12 (30.4 ± 1.09 µg mL−1) (Table 3, Fig. 1D).
After 2 and 8 weeks of follow-up, the DHA concentrations
slightly increased to 33.8 ± 1.57 µg mL−1 (n.s.) (Table S3†).
The initial AA concentrations in the RBCs (150 ± 3.90
µg mL−1) were only marginally reduced (136–138 µg mL−1) in
the first 6 weeks and then significantly (p = 0.001) dropped to
124 ± 3.53 µg mL−1 at week 12 (Table 3, Fig. 2), corresponding
to a mean decrease of 16.6 ± 3.31%. The relative AA amount
was statistically significantly reduced at all time points of the
intervention. In the follow-up period, the AA concentrations
increased, although not significantly, whereas the relative
increase was significant (p = 0.012 (week 14) and p = 0.001
(week 20)) (Table S3†).
Both the absolute concentrations and relative amount of LA
in the RBCs did not change in the course of the high-ALA diet
and follow-up period (Tables 3 and S3†). The concentration of
SFA, PUFA and Σn3 PUFA in the RBCs remained constant
during the study. However, the concentrations of MUFA and
Σn6 PUFA in the RBCs were significantly decreased after 12
weeks of the high-ALA diet (Table 3). The MUFA concen-
trations decreased (p = 0.019) from 210 ± 6.24 µg mL−1 at week
0 to 179 ± 5.89 µg mL−1 at week 12, while the Σn6 PUFA con-
Table 2 Daily energy and fat intake from 3-day dietary questionnaires
Week 0 Week 6
t-Testa
Week 12
t-Testa
An reMb
Mean ± SD Mean ± SD Mean ± SD p
Energy intake (kcal) 2910 ± 1181 2924 ± 820 2403 ± 524 n.s.
Total fat intake (g) 113 ± 40.3 128 ± 42.0 108 ± 24.3 n.s.
SFA (g) 31.1 ± 15.5 26.9 ± 11.0 n.s. 24.4 ± 9.83 n.s. 0.026
MUFA (g) 14.3 ± 6.88 14.6 ± 8.44 13.9 ± 6.14 n.s.
PUFA (g) 11.2 ± 7.02 23.3 ± 3.14 0.002 22.9 ± 5.87 0.004 <0.001
LA (g) 9.25 ± 5.93 9.14 ± 2.87 9.58 ± 3.34 n.s.
ALA (g) 1.39 ± 1.31 13.9 ± 0.34 <0.001 14.0 ± 0.53 <0.001 <0.001
AA (g) 0.09 ± 0.07 0.16 ± 0.18 0.10 ± 0.07 n.s.
EPA (g) 0.19 ± 0.52 0.02 ± 0.03 0.01 ± 0.03 n.s.
DPAn3 (g) 0.06 ± 0.06 0.04 ± 0.06 0.03 ± 0.06 n.s.
DHA (g) 0.15 ± 0.18 0.06 ± 0.06 0.05 ± 0.06 n.s.
The levels are shown at week 0, 6 and 12 of the high-ALA diet (14.0 ± 0.45 g d−1). AA: arachidonic acid; ALA: α-linolenic acid; EPA: eicosapentae-
noic acid; DHA: docosahexaenoic acid; DPAn3: docosapentaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; PUFA: polyun-
saturated fatty acids; SFA: saturated fatty acids; wk: week. a t-Test for paired samples with Holm–Bonferroni correction; significance level p ≤ 0.05.
b ANOVA for repeated measures (An reM); significance level p ≤ 0.05.
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Table 3 Concentration and relative amount of fatty acids in red blood cells
Week 0 Week 1 t-Testa Week 3 t-Testa Week 6 t-Testa Week 12 t-Testa An reMb
Mean ± SE Mean ± SE p (week 1–week 0) Mean ± SE p (week 3–week 0) Mean ± SE p (week 6–week 0) Mean ± SE p (week 12–week 0) p
C12:0 µg mL−1 <0.25 <0.25 — <0.25 — <0.25 — <0.25 — —
% of total FA — — — — — — — — — —
C14:0 µg mL−1 3.74 ± 0.10 3.02 ± 0.15 0.001 2.73 ± 0.16 <0.001 3.03 ± 0.15 0.026 3.09 ± 0.17 n.s. <0.001
% of total FA 0.37 ± 0.01 0.32 ± 0.01 n.s. 0.28 ± 0.01 n.s. 0.31 ± 0.01 n.s. 0.34 ± 0.02 n.s. <0.001
C14:1n5 µg mL−1 <0.25 <0.25 — <0.25 — <0.25 — <0.25 — —
% of total FA — — — — — — — — — —
C15:0 µg mL−1 1.75 ± 0.05 1.62 ± 0.06 — 1.67 ± 0.09 — 1.61 ± 0.07 — 1.68 ± 0.19 — n.s.
% of total FA 0.17 ± 0.01 0.17 ± 0.01 — 0.17 ± 0.01 — 0.16 ± 0.01 — 0.18 ± 0.02 — n.s.
C16:0 µg mL−1 196 ± 4.60 188 ± 3.00 — 187 ± 3.86 — 191 ± 5.60 — 184 ± 5.58 — n.s.
% of total FA 19.3 ± 0.08 19.7 ± 0.15 — 19.4 ± 0.16 — 19.5 ± 0.19 — 20.1 ± 0.15 0.002 0.029
C16:1n7 µg mL−1 2.65 ± 0.15 2.15 ± 0.12 — 2.30 ± 0.15 n.s. 2.44 ± 0.17 n.s. 2.35 ± 0.18 n.s. 0.032
% of total FA 0.26 ± 0.01 0.22 ± 0.01 — 0.24 ± 0.01 — 0.25 ± 0.01 — 0.25 ± 0.01 — n.s.
C17:0 µg mL−1 3.27 ± 0.07 3.03 ± 0.07 — 3.01 ± 0.12 n.s. 3.02 ± 0.09 n.s. 2.86 ± 0.10 0.039 0.012
% of total FA 0.32 ± 0.01 0.32 ± 0.01 — 0.31 ± 0.01 — 0.31 ± 0.01 — 0.31 ± 0.01 — —
C18:0 µg mL−1 154 ± 2.63 147 ± 1.92 — 148 ± 2.91 — 150 ± 3.41 — 143 ± 4.19 — n.s.
% of total FA 15.1 ± 0.11 15.4 ± 0.13 — 15.3 ± 0.08 — 15.4 ± 0.10 0.004 15.6 ± 0.13 <0.001 <0.001
C18:1n9 µg mL−1 135 ± 3.91 120 ± 2.44 0.036 121 ± 2.56 n.s. 122 ± 3.69 n.s. 115 ± 4.00 0.035 0.001
% of total FA 13.3 ± 0.18 12.5 ± 0.15 0.013 12.5 ± 0.16 0.014 12.5 ± 0.16 0.017 12.5 ± 0.16 0.023 <0.001
C18:1n7 µg mL−1 14.5 ± 0.46 12.9 ± 0.28 0.044 12.6 ± 0.34 0.016 12.4 ± 0.34 0.008 11.9 ± 0.42 0.010 <0.001
% of total FA 1.43 ± 0.02 1.35 ± 0.02 0.001 1.30 ± 0.02 <0.001 1.27 ± 0.02 <0.001 1.30 ± 0.02 0.002 <0.001
C18:2n6 µg mL−1 104 ± 3.60 97.9 ± 2.94 — 102 ± 3.60 — 103 ± 3.10 — 97.9 ± 3.69 — n.s.
% of total FA 10.3 ± 0.32 10.3 ± 0.29 — 10.5 ± 0.29 — 10.6 ± 0.30 — 10.7 ± 0.28 — n.s.
C18:3n6 µg mL−1 <0.25 <0.25 — <0.25 — <0.25 — <0.25 — —
% of total FA — — — — — — — — — —
C19:0 µg mL−1 <0.25 <0.25 — <0.25 — <0.25 — <0.25 — —
% of total FA — — — — — — — — — —
C18:3n3 µg mL−1 1.44 ± 0.10 4.65 ± 0.22 <0.001 5.47 ± 0.23 <0.001 6.25 ± 0.24 <0.001 5.80 ± 0.28 <0.001 <0.001
% of total FA 0.14 ± 0.01 0.49 ± 0.02 <0.001 0.57 ± 0.03 <0.001 0.64 ± 0.02 <0.001 0.63 ± 0.03 <0.001 <0.001
C20:0 µg mL−1 5.44 ± 0.12 4.41 ± 0.12 <0.001 4.34 ± 0.10 <0.001 4.30 ± 0.12 <0.001 3.91 ± 0.12 <0.001 <0.001
% of total FA 0.54 ± 0.01 0.46 ± 0.01 0.003 0.45 ± 0.01 <0.001 0.44 ± 0.01 <0.001 0.43 ± 0.01 <0.001 <0.001
C20:1n9 µg mL−1 3.14 ± 0.11 2.90 ± 0.07 n.s. 2.98 ± 0.09 n.s. 2.85 ± 0.11 0.003 2.67 ± 0.10 0.003 0.002
% of total FA 0.31 ± 0.01 0.30 ± 0.01 — 0.31 ± 0.01 — 0.29 ± 0.01 — 0.29 ± 0.01 — n.s.
C20:2n6 µg mL−1 2.04 ± 0.09 1.92 ± 0.09 — 2.00 ± 0.12 — 1.87 ± 0.10 — 1.83 ± 0.12 — n.s.
% of total FA 0.20 ± 0.01 0.20 ± 0.01 — 0.21 ± 0.01 — 0.19 ± 0.01 — 0.20 ± 0.01 — n.s.
C20:3n6 µg mL−1 15.5 ± 0.81 13.7 ± 0.68 0.014 13.1 ± 0.71 0.024 13.3 ± 0.71 0.009 12.2 ± 0.86 0.001 <0.001
% of total FA 1.53 ± 0.08 1.43 ± 0.07 n.s. 1.35 ± 0.06 n.s. 1.36 ± 0.06 n.s. 1.32 ± 0.07 0.035 <0.001
C20:4n6 µg mL−1 150 ± 3.90 136 ± 2.33 n.s. 138 ± 2.69 n.s. 137 ± 3.24 0.043 124 ± 3.53 0.001 <0.001
% of total FA 14.8 ± 0.14 14.3 ± 0.14 0.042 14.3 ± 0.12 0.035 14.0 ± 0.12 <0.001 13.5 ± 0.14 <0.001 <0.001
C20:5n3 µg mL−1 6.13 ± 0.51 7.33 ± 0.33 n.s. 8.38 ± 0.42 0.021 10.9 ± 0.67 <0.001 11.0 ± 0.64 <0.001 <0.001
% of total FA 0.60 ± 0.04 0.77 ± 0.03 0.006 0.87 ± 0.04 0.002 1.12 ± 0.06 <0.001 1.20 ± 0.06 <0.001 <0.001
C22:0 µg mL−1 17.7 ± 0.56 16.6 ± 0.39 n.s. 16.9 ± 0.39 n.s. 16.9 ± 0.54 n.s. 15.3 ± 0.51 0.026 <0.001
% of total FA 1.75 ± 0.04 1.75 ± 0.04 n.s. 1.75 ± 0.04 n.s. 1.73 ± 0.04 n.s. 1.67 ± 0.03 n.s. 0.020
C22:1n9 µg mL−1 2.42 ± 0.16 2.81 ± 0.30 n.s. 2.41 ± 0.16 n.s. 2.34 ± 0.23 n.s. 1.90 ± 0.20 n.s. 0.016
% of total FA 0.24 ± 0.02 0.29 ± 0.03 n.s. 0.25 ± 0.02 n.s. 0.25 ± 0.03 n.s. 0.21 ± 0.02 n.s. 0.042
C22:4n6 µg mL−1 31.6 ± 1.01 31.6 ± 1.14 n.s. 30.7 ± 1.02 n.s. 29.3 ± 1.15 n.s. 25.1 ± 1.07 <0.001 <0.001
% of total FA 3.13 ± 0.11 3.20 ± 0.10 n.s. 3.18 ± 0.09 n.s. 2.99 ± 0.08 n.s. 2.73 ± 0.07 <0.001 <0.001
C22:5n3 µg mL−1 25.9 ± 0.82 25.2 ± 0.59 n.s. 28.2 ± 0.80 n.s. 30.2 ± 1.03 0.033 32.3 ± 1.35 0.014 <0.001
% of total FA 2.55 ± 0.05 2.64 ± 0.05 n.s. 2.92 ± 0.06 <0.001 3.09 ± 0.07 <0.001 3.52 ± 0.10 <0.001 <0.001
C24:0 µg mL−1 45.6 ± 1.25 45.3 ± 0.81 — 46.6 ± 1.04 — 47.1 ± 1.15 — 44.0 ± 1.34 — n.s.
% of total FA 4.50 ± 0.08 4.75 ± 0.08 0.001 4.83 ± 0.10 <0.001 4.83 ± 0.08 0.007 4.81 ± 0.10 0.004 <0.001
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Table 3 (Contd.)
Week 0 Week 1 t-Testa Week 3 t-Testa Week 6 t-Testa Week 12 t-Testa An reMb
Mean ± SE Mean ± SE p (week 1–week 0) Mean ± SE p (week 3–week 0) Mean ± SE p (week 6–week 0) Mean ± SE p (week 12–week 0) p
C22:6n3 µg mL−1 41.0 ± 1.93 37.0 ± 1.32 n.s. 36.1 ± 1.37 n.s. 35.1 ± 1.06 0.010 30.4 ± 1.09 <0.001 <0.001
% of total FA 4.03 ± 0.16 3.90 ± 0.15 n.s. 3.74 ± 0.13 n.s. 3.62 ± 0.12 0.017 3.33 ± 0.11 0.001 <0.001
C24:1n9 µg mL−1 51.8 ± 1.88 50.4 ± 1.13 n.s. 50.6 ± 1.03 n.s. 50.0 ± 1.65 n.s. 44.4 ± 1.52 0.019 <0.001
% of total FA 5.10 ± 0.11 5.28 ± 0.10 0.003 5.25 ± 0.09 0.035 5.11 ± 0.11 n.s. 4.84 ± 0.09 n.s. <0.001
ΣTFA µg mL−1 1016 ± 22.0 955 ± 12.1 n.s. 966 ± 17.3 n.s. 977 ± 22.2 n.s. 918 ± 26.1 n.s. 0.015
ΣSFA µg mL−1 427 ± 8.49 408 ± 5.39 — 411 ± 7.59 — 418 ± 10.3 — 399 ± 11.3 — n.s.
% of total FA 42.1 ± 0.16 42.8 ± 0.24 n.s. 42.5 ± 0.16 n.s. 42.7 ± 0.16 0.001 43.5 ± 0.23 <0.001 <0.001
ΣMUFA µg mL−1 210 ± 6.24 191 ± 3.68 n.s. 192 ± 3.80 n.s. 193 ± 5.53 n.s. 179 ± 5.89 0.019 <0.001
% of total FA 20.7 ± 0.28 20.0 ± 0.23 n.s. 19.9 ± 0.24 n.s. 19.7 ± 0.24 0.023 19.4 ± 0.23 0.003 <0.001
ΣPUFA µg mL−1 378 ± 8.35 355 ± 4.74 n.s. 364 ± 7.20 n.s. 367 ± 7.43 n.s. 340 ± 9.73 n.s. 0.017
% of total FA 37.3 ± 0.23 37.2 ± 0.24 — 37.7 ± 0.20 — 37.6 ± 0.26 — 37.1 ± 0.26 — n.s.
Σn3 PUFA µg mL−1 74.4 ± 2.83 74.2 ± 1.43 n.s. 78.1 ± 1.80 n.s. 82.4 ± 2.01 n.s. 79.4 ± 2.24 n.s. 0.023
% of total FA 7.32 ± 0.19 7.79 ± 0.15 <0.001 8.10 ± 0.13 <0.001 8.46 ± 0.17 <0.001 8.68 ± 0.13 <0.001 <0.001
Σn6 PUFA µg mL−1 303 ± 6.55 280 ± 4.66 n.s. 286 ± 6.14 n.s. 285 ± 6.33 n.s. 261 ± 8.01 0.004 <0.001
% of total FA 29.9 ± 0.27 29.4 ± 0.29 n.s. 29.6 ± 0.25 n.s. 29.2 ± 0.26 n.s. 28.5 ± 0.25 0.001 <0.001
ΣEPA & DHA µg mL−1 47.1 ± 2.36 46.4 ± 1.44 n.s. 44.5 ± 1.46 n.s. 46.0 ± 1.32 n.s. 41.3 ± 1.27 n.s. 0.023
% of total FA 4.63 ± 0.19 4.67 ± 0.16 — 4.61 ± 0.13 — 4.73 ± 0.15 — 4.52 ± 0.11 — n.s.
Σn6/Σn3 PUFA 4.15 ± 0.13 3.81 ± 0.10 <0.001 3.68 ± 0.08 0.002 3.48 ± 0.09 <0.001 3.30 ± 0.07 <0.001 <0.001
AA/EPA 26.5 ± 1.55 19.3 ± 0.90 <0.001 17.0 ± 0.69 <0.001 13.3 ± 0.80 <0.001 11.8 ± 0.59 <0.001 <0.001
D5D index 10.1 ± 0.51 10.3 ± 0.46 — 10.9 ± 0.47 — 10.7 ± 0.52 — 10.8 ± 0.68 — n.s.
D6D index 0.15 ± 0.01 0.14 ± 0.01 n.s. 0.13 ± 0.01 <0.001 0.13 ± 0.01 <0.001 0.12 ± 0.01 <0.001 <0.001
% n3 in HUFA 27.0 ± 0.64 27.9 ± 0.55 0.010 28.6 ± 0.47 0.002 29.8 ± 0.49 <0.001 31.4 ± 0.47 <0.001 <0.001
% n6 in HUFA 73.1 ± 0.64 72.2 ± 0.55 0.010 71.5 ± 0.47 0.002 70.2 ± 0.49 <0.001 68.6 ± 0.47 <0.001 <0.001
The levels are shown as concentration [µg mL−1] in blood and as relative amount [%] of total fatty acids at week 0, 1, 3, 6, and 12 of the high-ALA diet (14.0 ± 0.45 g d−1). AA: arachidonic
acid; D5D/D6D index, delta-5/6 desaturase index: calculated according to ref. 41: D5D = C20:4n6/C20:3n6 and D6D = C20:3n6/C18:2n6; EPA: eicosapentaenoic acid; HUFA: highly unsaturated
fatty acids; indices of HUFA calculated as follows, modified from ref. 42: % n3 in HUFA = 100 × (C20:5n3 + C22:5n3 + C22:6n3)/(C20:3n6 + C20:4n6 + C22:4n6 + C20:5n3 + C22:5n3 +
C22:6n3); % n6 in HUFA = 100 × (C20:3n6 + C20:4n6 + C22:4n6)/(C20:3n6 + C20:4n6 + C22:4n6 + C20:5n3 + C22:5n3 + C22:6n3); MUFA: monounsaturated fatty acids: C14:1n5, C15:1n5,
C16:1n7, C17:1n7, C18:1n9, C18:1n7, C20:1n9, C22:1n9, 24:1n9; n.s.: not significant; SFA: saturated fatty acids: C10:0, C11:0, C12:0, C13:0, C14:0, C15:0, C16:0, C17:0, C18:0, C20:0, C21:0,
C22:0, C24:0; PUFA: polyunsaturated fatty acids: C18:2n6, C18:3n6, C18:3n3, C20:2n6, C20:3n6, C20:4n6, C20:5n3, C22:4n6, C22:5n3, C22:6n3; SE: standard error; TFA: total fatty acids; Σ n3
PUFA: C18:3n3, C20:3n3, C20:5n3, C22:5n3, C22:6n3; Σ n6 PUFA: C18:2n6, C18:3n6, C20:2n6, C20:3n6, C20:4n6, C22:2n6, C22:4n6; wk: week. a t-Test for paired samples with Holm–
Bonferroni correction; significance level p ≤ 0.05. b ANOVA for repeated measures (An reM); significance level p ≤ 0.05.
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centrations decreased (p = 0.004) from 303 ± 6.55 µg mL−1 at
week 0 to 261 ± 8.01 µg mL−1 at week 12 (Table 3).
The ratio of Σn6 to Σn3 PUFA significantly declined (p <
0.001) after 1 week of the high-ALA diet from 4.15 ± 0.13 (week
0) to 3.81 ± 0.10 (week 1) and further to 3.30 ± 0.07 after week
12 (Table 3). In the follow-up period, the Σn6/Σn3 PUFA ratio
increased (p = 0.002) again to 3.73 ± 0.13 (week 20)
(Table S3†).
Consistently, the ratio of AA to EPA dropped (p < 0.001)
time-dependently from 26.5 ± 1.55 (week 0) to 11.8 ± 0.59 at
week 12 and slowly increased (p < 0.001) in the follow-up
period to 17.3 ± 1.06 (Table 3). The activity of D6D decreased
(p < 0.001) in response to the high-ALA diet from 0.15 ± 0.01
(week 0) to 0.12 ± 0.01 at week 12 and increased (p < 0.001)
again in the follow-up period (week 20: 0.17 ± 0.01) (Table 3).
The percentage of n3 in HUFA increased from 27.0 ± 0.64
Fig. 1 Content of selected polyunsaturated fatty acids in red blood cells. Bars represent mean ± SE. The levels are shown as concentrations
[μg mL−1] and as relative amounts [%] of total fatty acids at week 0, 1, 3, 6, and 12 of the high-ALA diet (14.0 ± 0.45 g d−1) and at week 14 and 20 of
follow-up. AA: arachidonic acid (C20:4n6); ALA: alpha-linolenic acid (C18:3n3); DHA: docosahexaenoic acid (C22:6n3); DPAn3: docosapentaenoic
acid (C22:5n3); EPA: eicosapentaenoic acid (C20:5n3); wk: week.
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(week 0) to 31.4 ± 0.47 (week 12), whereas the percentage of n6
in HUFA decreased from 73.1 ± 0.64 (week 0) to 68.6 ± 0.47
(week 12) following the high-ALA diet (Table 3). A reversion of
this change could be observed in the follow-up period: n3 in
HUFA decreased again from 31.4 ± 0.47% (week 12) to 28.9 ±
0.63% (week 20) and n6 in HUFA increased from 68.6 ± 0.47%
(week 12) to 71.1 ± 0.63 (Table S3†).
Changes of oxylipin concentrations in the plasma
The changes in the concentration of free hydroxy- and di-
hydroxy-PUFA in the plasma were represented by the shift in
concentrations of their precursor PUFAs in the RBCs. As
shown exemplarily for selected oxylipins, representing the
metabolites of 5-LOX, 15-LOX and CYP catalyzed epoxygena-
Fig. 2 Concentration of selected free oxylipins in the plasma. Bars represent mean ± SE [pM]. The plasma concentrations of free oxylipins are
shown at week 0, 1, 3, 6, and 12 of the high-ALA diet (14.0 ± 0.45 g d−1) and at week 14 and 20 of follow-up. AA: arachidonic acid (C20:4n6); ALA:
alpha-linolenic acid (C18:3n3); DHA: docosahexaenoic acid (C22:6n3); DiHETE: dihydroxy eicosatetraenoic acid; DiHETrE: dihydroxy eicosatrienoic
acid; DiHDPE: dihydroxy docosapentaenoic acid; DiHODE: dihydroxy octadecadienoic acid; DiHOME: dihydroxy octadecenoic acid; EPA: eicosapen-
taenoic acid (C20:5n3); HDHA: hydroxy docosahexaenoic acid; HEPE: hydroxy eicosapentaenoic acid; HETE: hydroxy eicosatetraenoic acid; HODE:
hydroxy octadecadienoic acid; HOTrE: hydroxy octadecatrienoic acid; LA: linoleic acid (C18:2n6); LLOQ: lower limit of quantiﬁcation; SE: standard
error; wk: week.
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tion and hydrolysis by sEH, a similar but less pronounced
trend compared to the precursor PUFA was observed (Fig. 2).
5- and 15-LOX-derived hydroxy-PUFA from ALA, i.e.
9-HOTrE and 13-HOTrE, increased time-dependently from
693 ± 71.7 pM (week 0) to 1285 ± 106 pM (week 12) (p = 0.001)
and from 993 ± 113 pM (week 0) to 2569 ± 234 pM (week 12)
(p < 0.001) (Fig. 2, Table S4†). The highest concentrations of 9-
and 13-HOTrE were observed at week 12. The concentration of
the terminal dihydroxy-PUFA 15,16-DiHODE also increased
from 18 243 ± 2970 pM (week 0) to 24 795 ± 1802 pM (week 12)
(p = 0.033); however, it was less pronounced compared to ALA-
derived hydroxy-PUFA and, though not significant, the highest
concentration was observed at week 6 (28 086 ± 3631 pM).
LA-derived oxylipins remained unchanged; however, the
concentrations varied in the course of the trial (Fig. 2,
Table S4†). This is consistent with the LA concentration in the
RBCs that did not show significant changes in response to the
high-ALA diet.
For EPA-derived oxylipins, as exemplarily shown in Fig. 2
for 5-, 15-, 18- and 20-HEPE and 17,18-DiHETE, an increase
from week 0 to week 6 was observed followed by a slight
decrease at week 12 (except 15-HEPE).
For most of the AA-derived hydroxy- and dihydroxy-PUFA,
such as 5-, 15-, 20-HETE and 14,15-DiHETrE, a slight though
statistically not significant decrease in concentration after 1
week of ALA supplementation was observed (Fig. 2). Similarly,
no consistent shift of DHA-derived oxylipins was observed
(Fig. 2, Table S4†). Overall, the oxylipin levels were reflected by
the respective precursor fatty acid concentrations in the RBCs,
though changes in the oxylipin levels occurred at later time
points and were, due to higher SE, less pronounced compared
to the precursor fatty acids.
Discussion
Factors like age,43,44 BMI,44 smoking45 and genotype46 showed
an influence on the LC n3 PUFA status, especially on the con-
version from ALA to DHA. Recently, it has been shown that the
activity of endogenous EPA and DHA synthesis adapted during
evolution in the presence of these fatty acids in the diet.47
Several studies observed higher circulating relative DHA
amounts in women compared to men independent of dietary
intake48–50 and higher conversion rates from ALA and EPA to
DHA51 possibly due to the influence of estrogen on the PUFA
metabolism.52 Consequently, to minimize the variability, a
homogeneous collective of healthy, non-smoking men within a
narrow range regarding age (mean age 26.2 ± 4.53 years) and
BMI (24.9 ± 2.0 kg m−2) was chosen to investigate the eﬀect of
ALA on the LC n3-PUFA levels.
In addition, to study the eﬀect of a high daily ALA intake in
a Western diet on the EPA and DHA blood levels, it is crucial
to choose a study collective with low baseline EPA/DHA levels,
since the expected conversion of ALA to EPA and DHA is the
highest compared to subjects with a moderate or high EPA/
DHA status.
We selected probands basically eating a mixed Western diet
with a low meat and fish consumption and explicitly screened
for low blood LC n3 PUFA status. The relative ΣEPA + DHA
level in RBCs, similar to omega-3 index, was 4.15 ± 0.13% of
total fatty acids and comparable to the (low) mean omega-3
index of men in the U.S. and Germany which is associated
with the risk of cardiovascular disease.53
As expected, the high-ALA diet – providing an ALA amount
of about 4.7 en% – resulted in a strong increase in the ALA
levels in the RBCs. The incorporation of ALA (and other
PUFAs) into the RBCs is determined by the blood cell turnover
(the mean life span of a red blood cell is approximately 120
days in circulation) and thus the ALA and its bioconverted
longer chain n3 PUFAs EPA and DHA do not fully reach the
RBCs. Nevertheless, a 238 ± 24% increase of ALA concentration
in the RBCs was observed after one week.
The ratio of LA to ALA in the RBCs (74.8 ± 3.54) at baseline
is much higher than expected from the dietary supply of these
C18 PUFAs (LA/ALA intake ratio: 7.70 ± 3.75). Even after a
12-week intake of similarly high amounts of LA (9.38 ± 3.08
g d−1) and ALA (14.0 ± 0.45 g d−1) with a ratio of 0.67 ± 0.21, the
ratio of LA to ALA in the RBCs remained high (17.5 ± 0.97). The
possible reasons for this could be that ALA significantly diﬀers
from LA in absorption, tissue distribution, membrane incorpo-
ration, and/or degradation. Most likely, a high percentage of
60–85% of ALA is rapidly degraded by beta-oxidation54 before it
becomes available for tissue distribution and membrane
integration as well as elongation and desaturation to EPA.
The high-ALA diet also aﬀected the concentrations of other
PUFAs with significantly increased EPA and DPAn3 as well as
significantly decreased DHA and AA concentrations in the
RBCs. Of note, the concentration of EPA was with a change of
about 5 µg mL−1 similarly elevated as the ALA concentration.
The percentage increase in the concentrations and relative
amounts was more pronounced for EPA (week 12: 97 ± 21%
and 112 ± 17%, respectively) compared to DPAn3 (week 12:
27 ± 7% and 39 ± 4%, respectively). It is likely that increasing
EPA levels are the result of a conversion from ALA; however, it
cannot be excluded that the retroconversion of DHA to DPAn3
and EPA occurred, which would also (partly) explain decreas-
ing DHA concentrations. These results are consistent with pre-
vious studies, where a dose-dependent and higher increase of
EPA compared to DPAn3 was observed in the RBCs55,56 and
plasma and platelet phospholipids.35 However, supplementing
EPA is more eﬃcacious compared to ALA in raising the EPA
blood levels.19 A six-week supplementation of 600 mg EPA per
day, which corresponds to a ∼10-fold increase compared to the
median intake in Germany, resulted in a 138% increase of the
relative serum phospholipid EPA amount.57 A higher dose of
2.0 g EPA per day caused a 325% increase of the relative EPA
amount in the RBCs.58
The initial ALA concentrations were also low (1.44 ± 0.10
µg mL−1) compared to the EPA concentrations (6.13 ± 0.51
µg mL−1) and the ratio of ALA to EPA increased in the first
three weeks and slightly decreased thereafter. The high-ALA
diet led to a strong increase of ALA in the RBCs. However, as
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discussed before, with increasing ALA concentrations, the rate
of ALA catabolism increases24 as observed in the moderate
drop of the ALA levels between week 6 and week 12. This may
also explain the steady state in the EPA concentrations
between week 6 (10.9 ± 0.67 µg mL−1) and week 12 (11.0 ±
0.64 µg mL−1).
The observed reduction of the DHA levels is surprising and
in contrast to earlier studies, which determined a conversion
(rate) of ALA to DHA of 0.5–5%.16–21 However, in these studies,
the ingested ALA amount was low (1.0–3.5 g)17,59 compared to
ours. A study with a similar design as our study including a
high daily ALA dose (15.4 ± 7.5 g) showed no significant eﬀect
on relative DHA amounts in plasma and platelet phospholi-
pids,35 possibly due to low sample size (n = 7), an inhomo-
geneous initial LC n3 PUFA status and a highly variable ALA
intake (high SD). In contrast, we observed significantly decreased
DHA concentrations and relative amounts in the RBCs in
response to the high-ALA diet. It should be noted that the bio-
logical variability of fatty acid concentrations in the RBCs is
small compared to plasma and plasma phospholipids.60
Nonetheless, several studies indicated a tendency for declining
DHA levels in response to high ALA consumption, which was in
most cases marginal and not statistically significant.35,61–69 One
possible explanation for the decreasing DHA concentrations in
the RBCs may be that DHA accumulates in the nerve cells of the
brain.70 While human studies are limited to blood as the
medium of investigation, animal studies demonstrated that the
conversion of ALA to EPA and DHA is tissue specific. In a rat
study with high-ALA chia seed supplementation, the accumu-
lation of DHA in the heart and liver was observed, while the
plasma DHA concentrations remained constant.71
In our study, the ALA intake from the background diet was
tightly controlled and hence the variability of total daily ALA
intake in the intervention period was low (∼1.9 g). Only a few
other studies found a significant reduction of the relative DHA
levels in mononuclear cell phospholipids66 and platelet phospha-
tidylcholine69 in response to an ALA enriched diet. However, the
LA amount in the diet of the studies by Kew et al. (13.1 and
16.2 g d−1)66 and Weaver et al. (22.5 g d−1)69 was much higher
than in our study (<10 g) based on food questionnaires (Table 2).
The conversion eﬃciency of ALA to DHA appears to be
aﬀected by a high LA, ALA and total PUFA intake. A rat study
observed the highest conversion of ALA to DHA as a result of
feeding a narrow dietary range of 1–2 en% LA and 1–3 en%
ALA, while the DHA levels were suppressed to basal levels
(∼2% total fatty acids) with the total PUFA levels above
3 en%.72 Excessive LA and ALA compete with LC n3 PUFAs for
the rate-limiting enzyme Δ6-desaturase.73 Δ6-desaturase cata-
lyzes the desaturation of LA to GLA, of ALA to stearidonic acid
(C18:4n3) and also of tetracosapentaenoic acid (C24:5n3) to
tetracosahexaenoic acid (C24:6n3), which is finally shortened
to form DHA by peroxisomal β-oxidation.15
The intake of LA, AA, EPA, DPAn3, and DHA did not signifi-
cantly change during the intervention compared to baseline
(3-day dietary questionnaires Table 2). In addition, the ALA
intake from the background diet (minus the ALA intake via the
daily linseed oil ingestion) did not change between week 0,
week 6 and week 12. On the other hand, the intake of EPA,
DPAn3, and DHA via the background diet was slightly
decreased, possibly due to the advice to avoid oily fish meals
during the intervention time. However, it seems unlikely that
this statistically insignificant decline caused the observed
decrease in the DHA concentrations in the RBCs.
However, it should be noted that estimates of dietary fat
intake relied on self-reported data and are potentially biased
by food choice, incomplete dietary protocols and methodologi-
cal limitations associated with accurate fatty acid composition
data in food databases.74
The beneficial health eﬀects of LC n3 PUFA are believed to
be (partly) mediated by oxidized mediators formed in the AA
cascade.10 A correlation between higher levels of precursor n3
PUFAs (e.g. EPA and DHA) and their oxylipins was demon-
strated in diﬀerent intervention studies.75–79 Accordingly, in
the present study, the changes of the oxylipin levels in the
plasma are generally reflected by the changes of the respective
precursor fatty acids in the RBCs. As expected, the levels of
ALA-derived oxylipins increased in response to the higher
dietary intake of ALA. In contrast to the ALA concentrations in
the RBCs, which increased more than 3-fold after only 1 week
of ALA supplementation, ALA-derived oxylipins were only
slightly but not significantly elevated. Moreover, whilst the ALA
concentration in the RBCs seemed to reach a steady state after
6 weeks of the high-ALA diet, ALA-derived oxylipins, such as
hydroxy-PUFA 9- and 13-HOTrE, increased steadily until week 12
up to 1.9-fold and 2.6-fold, respectively. The slower and less pro-
nounced rise of ALA-derived oxylipins compared to their precur-
sor fatty acid was not observed for DHA-derived oxylipins com-
pared to the blood cell concentrations of DHA in a similar
study.78,79 A possible explanation is the lower baseline concen-
tration of ALA compared to DHA, which might have led to a
more rapid increase and the higher supplemented dose.77
With regard to oxylipin formation, ALA is mostly discussed
as a precursor of LC n3 PUFA;80 therefore, the biological role of
ALA-derived oxylipins is only poorly understood. Some studies
demonstrated positive biological eﬀects of ALA-derived oxyli-
pins;81,82 however, further investigation of these mediators
needs to be carried out as ALA-derived oxylipins are present in
relevant concentrations in humans on a Western diet.10
Consistent with the elevated levels of EPA in the RBCs (1.8-
fold increase at week 6), a high-ALA diet leads to increasing
concentrations of EPA-derived hydroxy- and dihydroxy-PUFA in
the plasma (∼1.3- to 1.8-fold at week 6). The higher levels of
EPA-derived oxylipins upon a high-ALA diet may have ben-
eficial health eﬀects, e.g. 18-HEPE – a precursor of pro-resol-
ving and anti-inflammatory E-series resolvins83 – concen-
trations increased 1.7-fold at week 6. However, it has to be
noted that direct supplementation with EPA raises the EPA-
derived oxylipin levels more eﬃciently.84
Although the DHA concentrations in the RBCs were signifi-
cantly lowered in response to the high-ALA diet, the DHA-
derived oxylipin levels showed no consistent shift towards
lower levels.
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The conversion rates of ALA to EPA and DHA as well as the
formation of oxylipins from n3 PUFA are influenced by the
presence of n6 PUFA competing for the same enzymes.15,85
Several studies demonstrated that n3 PUFA supplementation
leads to declining AA and AA-derived oxylipin concentration;
however, the results were heterogeneous between diﬀerent
intervention studies.84 Despite the significant decrease of AA
in the RBCs in the present study, only a slight but not signifi-
cant decline of AA-derived oxylipins, e.g. hydroxy-PUFA 5- and
20-HETE, was observed, while no eﬀect was observed for, e.g.,
the 15-LOX product 15-HETE.
Similar results were obtained for LA-derived oxylipins and
no relevant reduction in response to high-ALA intake was
observed. Most likely, the excess of LA in the diet (and conse-
quently in the RBC membrane concentration) was too high to
be modified by a high-ALA diet. A decrease of the LA/ALA ratio
(from 74.8 ± 3.54 (week 0) to 17.5 ± 0.97 (week 12)) and the
ratio of LOX-derived hydroxy-PUFA 9-HODE/9-HOTrE (19.4 ±
1.04 (week 0) to 10.6 ± 0.68 (week 12)) and 13-HODE/13-HOTrE
(from 20.5 ± 1.39 (week 0) to 7.73 ± 0.78 (week 12)) results
from elevated ALA and ALA-derived oxylipin concentrations
with constant LA and LA-derived oxylipin concentrations.
A reduction of LA and its oxylipins is assumed to be beneficial,
as negative health eﬀects were observed for LA metabolites
such as sEH products of the CYP-derived epoxy-PUFA.86–88
A reduction of the LA metabolite 9,10-DiHOME by supplemen-
tation with a lower (6 g d−1) dose of ALA compared to our
study was demonstrated by Caligiuri et al. in young individuals
(19–28 years),89 after only 4 weeks of the intervention.
However, the participants had to abstain from dietary oils,
which might have altered their normal eating habits, thus,
leading to shifts in the fatty acid and oxylipin pattern.
Conclusions
Our results demonstrate that a high-ALA diet of 14.0 ± 0.45
g day−1 – which is 8–12 times higher than the common intake
recommendation for this essential fatty acid – results in a
significant increase in ALA, EPA and DPAn3 concentrations in
RBCs and a significant decline in DHA concentrations.
However, the ΣEPA + DHA concentration in RBCs – which is
associated with cardiac, cerebral, and general health status –
was not aﬀected in response to a high-ALA diet. The changes
in the plasma oxylipin levels were generally reflected by their
precursor fatty acids in RBCs. The high-ALA diet failed to
modulate LA and LA-derived oxylipins. Our results demon-
strate on both the fatty acid as well as the oxylipin level that on
a Western diet (with high LA intake), ALA is not a significant
source for endogenous EPA and DHA levels.
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